Grace M Aldrovandi, MD, Children’s Hospital, Associate Prof. of Pediatrics, University of Southern California, Los Angeles, California

Dr. Aldrovandi remarks about the evidence that early treatment for children is critical especially before puberty to permit more normal development. She defines the need for more trials to better understand the pathogenesis of HIV in children, and quicker access to adult approved treatments. She also advocates for more regular testing of women, and access to treatment in appropriate doses for all people young and old.

Jared Baeten, MD, PhD, Associate Professor, University of Washington, Seattle, Washington

(Deborah Donnell, PhD) They presented the data for a two-year study for discordant couples in which they looked at HIV transmission between the couples throughout the study.  This study demonstrated the usefulness of ARV treatment in preventing transmission to sexual partners. They and others through more studies will evaluate the benefit of long-term ARV treatment in preventing transmission. They will discuss future research which will look at Pre-exposure prophylaxis.


Per Bengsston, MD, PhD, Senior Vice President for Development, Bionor Immuno

Dr. Bengsston Vac 4x is a cocktail vaccine designed to target cell based immunity.  He will complete the phase II study summer 2010 with results presented in October 2010.  Their new studies will be given with ARV’s in one case and to study the preventive capability in the other. He will talk about the immune benefit and repair with this compound. He will also discuss another compound in early development which designed to create immune activation.  

Chris Beyrer, MD, MPH, Director, Center for Public Health & Human Rights, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland

He covers what prevention methodology is being studied today without MSM candidates or for people who have other than vaginal intercourse.  He will also cover secondary prevention through PreP or pre-exposure prophylaxis. He discusses the cost effectiveness and economics of this approach in developed worlds. He also covers the welcome change to include social structural drivers in prevention by the Federal Government which was presented at CROI by Kevin Fenton of the CDC.


Pamela Bjorkman, MD, Professor, California Institute of Technology, Pasadena, California

Dr. Bjorkman is in the field of basic science, working to create a totally new concept to vaccination for HIV.  The concept includes designing a new antibody in the lab through engineered immunity which will not be subject to the mutation. She will explain how they plan to insert the gene into to host using gene therapy.


Dennis Burton, PhD, Professor, Scripps Research Institute, La Jolla, California

He and others have recently found antibodies (proteins found in the blood) which seem to be better able to recognize the HIV virus being much more specific and potent than past antibodies. His goal is to find a way to induce them into the body as a vaccine then the body should begin to make that antibody and mount a preventative response.  He tries to couch this in a realistic and hopeful as a vaccine after much more research still to conduct.
Jacqueline Capeau, MD, Laboratoire de Biologie Cellulaire, Paris, France


She presented at the CROI on the stability, diagnosis and treatment of Hepatic steatosis and NASH (hepatitis). She covers the personal factors, metabolic and adiposity in HIV infected individuals, as well as lipid, glucose and diabetes in severity of hepatic steatosis. Another aspect is the complications that can trigger or make worse from hepatic Steatosis are accelerated aging and CVD and lipodystrophy.  She also explains the benefits of lifestyle changes.


John Coffin, PhD, Professor, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts & CROI Conference Co-chair

Dr. Coffin discusses some of the interesting findings in basic science at this years CROI, such as the difference presented by Guido Silvestri, and his work comparing difference in outcomes of SIV in two difference species of Monkeys, specifically in the central memory T-cells.  He also covers Dr. Goffs presentation on XMRV and how much time it takes to properly research such a new virus to fully enough understand it to provide clinically useful information. He covers some of the interesting RNAi and turning off specific genes and how that might effect replicating cells and yet another very large and labor intensive project.

Cal Cohen, MD, Director, CRI New England, and Harvard Medical Medical School
He covers the data he presented at the CROI including, other single tablet regimens, and alternatives to ritonavir boosting. He covers the larger phase three studies to get the compound into the market place around 2012 if all goes well.


Lynda Dee, Director, AIDS ACTION Baltimore, and AIDS Treatment Activists Coalition, Baltimore, Maryland


Lynda delivered the first Annual Martin Delaney Lecture given at the “CROI Young Investigators Lecture”. Lynda spoke about this lecture and Marty Delaney, activism as a whole and the reasons why we need to keep on improving and reshaping our activist work. 



Deborah Donnell, PhD, HPTN SDMC Co-Principal Investigator, Statistical Center for HIV/AIDS Research & Prevention


(Jared Baeten, MD, PhD). They presented the data for a two-year study for discordant couples in which they looked at HIV transmission between the couples throughout the study.  This study demonstrated the usefulness of ARV treatment in preventing transmission to sexual partners. They and others through more studies will evaluate the benefit of long-term ARV treatment in preventing transmission. They will discuss future research which will look at Pre-exposure prophylaxis.


Rick Elion, MD

Presents some of the studies that make a compelling case for test and treat or “Treatment as Prevention” which should be included as a critical part of the compendium of prevention measures that we currently have available. He and Cal Cohen also explain some of the issues around securing the best medical advice and connecting all physicians in small and large practices to current information in the way in which they want to see that information.

Kevin Fenton, MD, Director of the CDC, HIV, Hepatitis & TB Program
He describes the CDC prevention program, raising the profile of HIV, Hepatitis and TB in an effort to reduce disease and death. He also covers some of the new strategic plan, along with the National AIDS Strategy which provides a framework for his work at the Agency in a time of fiscal crisis one the one hand and dire need for more prevention resources on the other hand
Joel Gallant, MD, Johns Hopkins University Hospital, Baltimore, Maryland

Dr. Gallant reviews with us the several studies that demonstrated clinical implications such as boosted Atazanavir is as effective as Efavirenz, comparisons of the Gilead quad pill with atripla and atazanavir with only some concern for renal toxicity in lab values not necessarily in kidney function. He’ll cover his expectations for treatment simplification in the future, when to start, and test and treat research.

Stephen Goff, PhD, Professor of Microbiology, Immunology & Biochemistry & Molecular Biophysics at Columbia University


He is researching a virus, called XMRV that may cause prostate cancer.  He is currently looking at the origin of the Zoonotic transmitted virus, its pathogenesis, modes of transmission and its replication location and sequence. He and others are currently evaluating the potential deleterious effects of XMRV in humans. 


Diane Havlir, MD, Professor of Medicine at University of San Francisco, California

She presented some of the epidemiology of TB being the largest co-morbidity in HIV and some of the new drugs which have recently been studied for TB.  She discussed the need for sensitive diagnostic tests which are currently under study to more quickly and accurately diagnose TB, and understanding the transmissibility, re-infectivity, re-activation, pathogenesis and cure of TB and other work her group is conducting.

Robert Heimer, MD, Professor of Medicine, Yale University School of Medicine, Department of Epidemiology & Public Health


He covers his research around how long the hepatitis C virus remains active and the virus transmissible within various needles and under specific conditions.  He covers the aspects of the study which now demonstrate scientifically the importance of needle exchange programs at least in the high prevalence areas.


Priscilla Hsue, MD, Associate Professor, University of California, San Francisco, California


She presented data to support changes in treatment guidelines with HIV and cardiovascular disease or risk.  She recommends the controllable risk factors be looked at especially smoking reduction or cessation.  Others controlling lipids, blood pressure or controlling glucose.  She will also explore with us some of the kind of studies that may be important to answer, important questions such as when to start ARV therapy to reduce cardiovascular risk.


Peter Hunt, MD, Assistant Adjunct Professor of Medicine, University of San Francisco, San Francisco, California

Dr. Hunt projects the issues of elite controllers in the face of more aggressive treatment paradigms today including the new treatment guidelines. He makes comparisons of people with HIV controllers compared to non-controllers, and adjust for CVD and other risk factors to specifically determine the HIV effect.

Grace McComsey, MD, Chief, Division of Pediatric Infectious Diseases & Rheumatology & Associate Professor of Medicine & Pediatrics at Case Western Reserve University, Cleveland, Ohio


She presented the difference in decrease in bone density with different ARV’s, and will conduct other studies to tease out the gender differences. She will also speak to work being conducted in lipoatrophy, prevention for cardiovascular disease, prevention of osteopenia/osteoporosis and the benefits of the replenishment of Vitamin D deficiency through supplementation.


James McIntyre, MD, University of the Witwatersrand, Chris Hani Baragwanath Hospital, Johannesburg, South Africa
Dr. McIntyre, reviews the presentation regarding the study for ARV naïve women, to better understand nevirapine resistance for those who had used it for mother to child transmission prevention.  The results will inform future treatment choices for women in developing world treatment settings.  He will advocate for better immune and virologic markers to know better when and with what to start ARV treatments.
Sherene Min, MD, Director of Development, GlaxoSmithKline


She presented data on the new next generation integrase inhibitor, 572. Their are collaborating with Shinogi, with this new compound that is revealing some positive responses.  She will cover the resistance profile, back up compound, genetic barrier to resistance, lack of class cross resistance, phamacokinetic data, other drug/drug interactions, low milligram once daily dosing and timeline. She will also study the potential to move from the previous integrase inhibitors and co-formulation potential from within ViiV/Glaxo and Pfizer or outside the companies as well.  


Andrew Owen, BSc, MSc, PhD, Director, Molecular & Pharmacogenetic Components of LHPG Research, Department of Pharmacology, University of Liverpool, School of Biomedical Sciences


He covers a burgeoning field of pharmacogenomics, to detect differentiation in plasma concentrations in drugs and how that may affect different individuals.  He will describe the possible collection of individual genomic data that may suggest dose correction to reduce possible resistance on the one hand and potential toxicities on the other.


Holly Rawizza, MD, Brigham & Women’s Hospital, Boston, Massachusetts


Her program was to determine how best to manage treatment using either CD4 monitoring or viral load monitoring. They also included counseling in the study and found that over half of the treatment failures were missed when only using CD4 in resource limited settings. She covers how and where the lab tests are completed and for whom they are most necessary.


Kevin Robertson, PhD, University of North Carolina, Chapel Hill. Department of Neurology


He conducted a study to determine what happened neurocognitively when we put individuals on ART. He followed this study with some lab work to better understand the toxicities of the drugs themselves to the brain and plan further research in an effort to determine what the best treatment is for patients with CNS in mind.


Barbara L. Shacklett, PhD, Associate Professor, University of California, Davis, California
Dr. Shacklett reviewed elite controller research that she and others have conducted, and her collaboration in the Woman’s Interagency HIV Study. She will discuss her focus on more research for women for the social, ethical reasons but also for the intriguing information to be learned there are curious unique pathogenic differences in women in the mucosal and other immune system areas, as well as the reproductive tract.
Kimberly Smith, MD, Rush Medical Center, Chicago, Illinois

Dr. Smith presented data at this years CROI which made it clear that there is a disproportionate risk within some special populations and urban vs. some rural areas. Comparisons were made between some major US cities and some cities in Sub-Saharan Africa. She makes the case for action based upon the research and testing initiatives that we’ve conducted to improve the prevalence rate, and overcome barriers to regular testing and enrollment into research, treatment and care programs.

Bruce Walker, MD, Director of Ragon Institute, Ragon Institute of MGH, Charlestown, Massachusetts


He gives us a picture of some of the history of individuals who seemed to tolerate the virus much better than those who more regularly progress to disease.  He expresses his interest in learning how the controllers keep control of their immune system while others do not.


Brian Williams, MD. South African Center for Epidemiologic Modeling and Analysis, Cape Town, South Africa
Dr. Williams explains his work to move the “test and treat” concept forward thru studies to evaluate the benefit in communities with a high prevalence of HIV.  He will also cover fiscal issues, adherence follow-up and the requirement of an effective community medical infrastructure in place before roll out. 
Copyright 1995-2010 The International Foundation for Alternative Research in AIDS, Inc. (IFARA) 501(c)(3) All Rights Reserved